Abzena PLC Annual Report and Accounts (8818R)

TIDMABZA

RNS Number : 8818R

Abzena PLC

19 June 2018

Abzena plc

Annual Report and Accounts for the Year Ended 31 March 2018

Cambridge, UK, 19 June 2018 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, announces that its Annual Report and Accounts for the year ended 31 March 2018, is now available on the "Investors" section of the Group's website at http://www.abzena.com/about/investor-information/results-presentations/

Printed copies of the Annual Report and Accounts are available from the Company Secretary, Abzena plc, Babraham Research Campus, Babraham, Cambridge CB22 3AT, UK.

-Ends-

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive Officer               [phone] 
   Numis (Nominated Adviser and Broker) 
    Clare Terlouw / James Black / Paul Gillam        [phone] 
    N+1 Singer (Joint Broker) 
     Aubrey Powell / Liz Yong                        [phone] 
   Instinctif Partners                               [phone] 
    Melanie Toyne Sewell / Rozi Morris /              [e-mail] 
    Alex Shaw 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

   --      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --      Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --      Proprietary site-specific conjugation technologies and novel payloads for ADC development; 
   --      GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and 
   --      GMP analytical services for biopharmaceutical manufacturing projects. 

For more information, please see www.abzena.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ACSZMGMVMLKGRZM

(END) Dow Jones Newswires

June 19, 2018 07:28 ET (11:28 GMT)